NasdaqGS:INBXBiotechs
A Look At Inhibrx Biosciences (INBX) Valuation After Stifel Nicolaus Initiates Buy Coverage
Stifel Nicolaus has initiated coverage on Inhibrx Biosciences (INBX), highlighting upcoming clinical data for ozekibart in chondrosarcoma and advanced colorectal cancer as key near term regulatory and readout milestones for investors to monitor.
See our latest analysis for Inhibrx Biosciences.
Stifel Nicolaus’s new coverage and focus on upcoming ozekibart readouts arrives after a volatile run, with a 7 day share price return of 18.48% and a very large 1 year total shareholder return. This...